Expression of CD5 and CD23 on B cells of patients with rheumatoid arthritis, systemic lupus erythematosus and Sjögren's syndrome. Relationship with disease activity and treatment.
CD5+ and CD23+ lymphocytes were determined in peripheral blood of patients with rheumatoid arthritis (RA) (n = 56), systemic lupus erythematosus (SLE) (n = 20) and primary Sjögren's syndrome (pSS) (n = 21). No definite correlation between the numbers of CD5+ or CD23+ cells and most of the parameters of disease activity was found. A significant correlation (r = 0.59, p = 0.005) between rheumatoid factor levels and numbers of CD23+ cells was found in RA patients not taking disease modifying agents. For SLE and pSS no signification associations with autoantibody production were found. In conclusion, although CD5+ and CD23+ B cells might be important in the pathogenesis of autoimmune diseases, determination of these subsets in peripheral blood of RA, SLE or pSS patients provides no clear useful clinical information for the individual patient.
Ebo
D
D
Department of Immunology, Allergiology and Rheumatology, University of Antwerp, Belgium.
DeClerck
L S
LS
Bridts
C H
CH
Stevens
W J
WJ
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000032:analysis*; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D001327:Autoimmune Diseases / Q000097:blood / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D016175:B-Lymphocyte Subsets / Q000737:chemistry; D018956:CD5 Antigens; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000097:blood / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D012859:Sjogren's Syndrome / Q000097:blood / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology
D015703:Antigens, CD; D018956:CD5 Antigens; D007166:Immunosuppressive Agents